The market on Monday

Trump has said that his birthday wish is peace for the world.

BREAKING: The Social Security trust fund is on track to run out of money in late 2032, its trustees said. It's three months sooner than projected last year.

$SMMT 🙌

🚨 $SMMT Insider Buy Soni Manmeet Singh (Director) bought 50,000 shares ($722.25K) Jun 4 | Price: $14.84 52W: $13.83–$30.98 averageinsider.com/accession…

Every stock you don't own looks like this right now

$SMMT leadership is putting their money where their mouth is. Audit committee just greenlit affiliates to load up on shares via the ATM program, and the C-suite is signaling they're ready to buy. When the insiders are aggressively accumulating, you pay attention. The fundamentals are shifting; keep this one on the radar. 📈 🐂 Bull Level: Reclaim $16.00 to trigger a move toward $20.00 . 🐻 Bear Level: Holding $13.80 is mandatory; a breakdown here risks a test of the lower range.#SMMT #Biotech #InsiderBuying #StockMarket #hovdid

🔍 𝗟𝗔𝗥𝗚𝗘 𝗛𝗘𝗗𝗚𝗘 𝗙𝗨𝗡𝗗 𝗕𝗨𝗬𝗦 🔎 5-star Hedge Fund, DE Shaw, 𝗛𝗲𝗮𝘃𝗶𝗹𝘆 𝗕𝗢𝗢𝗦𝗧𝗘𝗗 their $SMMT stake in Q1 - as per latest 13F filing. They're now 1 of the top 10 LARGEST Shareholders of Summit. David's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 123.47% in the past 3 yrs

Did you listen to Trump when he told you to “buy $DELL” at $240?

The stock market on Monday

Biotech 🚀

$GUTS catalyst soon

$GUTS Fractyl Health stock, great day and bottom breakout. large upside price gap at stockconsultant.com/?GUTS

New business model just dropped..

Why the hell is the president adding the stock symbol? Cmon man…. This is all soooooo embarrassing.

Huge!🚀

Some bio names trading near or sub EV some catalyst Coming up in these names. (Some garbage but some may have some value that isn’t appreciated. Financials data could be outdated) Took some time to make this go easy on me 😅 $ABEO- BLA-UX111 - (ABO-102) Sanfilippo syndrome type A (MPS IIIA) (milestones upon approval-30M upfront 10% in sales from RARE $AGIO- H2 2026 p2 readout Sickle cell disease ( ton of call buying for Dec 2026 expiration) $AKBA- will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. (Currently in p2 for FSGS), (Entering Phase 2 basket trial in rare kidney diseases, including IgA nephropathy, lupus nephritis and C3 glomerulopathy, in the second half of 2026.)(entering a Phase 1 clinical trial in acute kidney injury (AKI) associated with cardiac surgery, in the first half of 2026.) $BLRX- P1 1H data 2027 in Glioblastoma $CRBP- (Q4 data Solid tumors, Locally advanced or metastatic urothelial carcinoma)(update in mid2026 from discussions with FDA regarding registrational study protocols for HNSCC and cervical cancer.) $FATE- H2 2026 in p1 Solid Tumors $FBIO- expansion of Emrosi $OMER- (pre clinical data H2 26’ for Cocaine use disorder (CUD)) (Q4 p3 data nocturnal hemoglobinuria (PNH))** $SNGX- H2 p3 interim data for Cutaneous T-Cell Lymphoma $VNDA- interim data 2026 p3 for Major depressive disorder (MDD)(PDUFA December in Generalized pustular psoriasis) $VYGR- (H2 p1 VY7523 data Alzheimer's disease)(P1a VY-TAU01 H2 Alzheimer's disease) $KURA- (H2 26’ p1 FLAG-IDA or LDAC for the treatment of NPM1-mutant or KMT2A-rearranged acute myeloid leukemia (AML))(H1 26’ p1 Clear cell renal cell carcinoma (ccRCC))(H1 p1 Acute myeloid leukemia (AML)) $CTMX-After cash raise* (late 26’ Initial CX-801 PROBODY Interferon-alpha-2b Phase 1 combination data with KEYTRUDA®(pembrolizumab) in melanoma expected by the end of 2026) $XBI $IBB

Dollar Land this week!

New Analyst Recommendation $CRBU 📈🧬🦌 $32 - buy - Brookline Capital - 03/05/26 $13 - outperform - Evercore ISI - 03/06/26 $13 - buy - Clear Street LLC - 03/05/26 $10 - outperform - RBC Capital - 03/05/26 $9 - buy - HC Wainwright & Co - 03/06/26 $8 - buy - Citi - 03/06/26 $7 - buy - Truist Securities - 03/06/26 $4 - outperform - Leerink Partners - 03/10/26